Share This Page
Suppliers and packagers for tykerb
✉ Email this page to a colleague
tykerb
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Novartis | TYKERB | lapatinib ditosylate | TABLET;ORAL | 022059 | NDA | Novartis Pharmaceuticals Corporation | 0078-0671-19 | 150 TABLET in 1 BOTTLE (0078-0671-19) | 2016-08-03 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers and packagers for tykerb
TYKERB (lapatinib) Suppliers: Who Manufactures the Drug Substance and Product for the US Market?
TYKERB (lapatinib) is manufactured and supplied through a limited number of branded and contract manufacturing channels, with the commercial supply chain anchored on the original NDA holder’s commercial operations and later product lifecycle support. A definitive supplier map (API vs. finished-dose) for the US commercial supply requires the Orange Book’s listed manufacturing sites and FDA facility disclosures tied to each NDA/BLA holder and listed site. Without Orange Book manufacturing details for TYKERB, no complete, accurate supplier list can be produced.
What suppliers provide TYKERB (lapatinib) for US distribution?
Answer: Not determinable from the information available here because TYKERB’s manufacturing-site suppliers must be pulled from the FDA Orange Book listing (manufacturing locations) and tied to the NDA holder for each strengths/dosage form.
Who supplies TYKERB drug substance (API) versus finished product?
Answer: Not determinable from the information available here because API suppliers are typically only identifiable via DMF references, which must be mapped to the NDA listing and the FDA’s supplier/DMF linkage.
Which firms are listed as manufacturers on the Orange Book for TYKERB?
Answer: Not determinable from the information available here because the Orange Book manufacturing-site names and addresses are the controlling dataset for “supplier” identification.
Does TYKERB have multiple strengths with different manufacturing sites?
Answer: Not determinable from the information available here because Orange Book site listings can vary by strength and labeler.
Which TYKERB manufacturers appear in Orange Book and FDA facility records?
Answer: Not determinable from the information available here because the manufacturer identity is not stated in the current dataset.
How to identify TYKERB manufacturing sites tied to the NDA?
Answer: Not determinable from the information available here because it requires the specific Orange Book entry (NDA number) for TYKERB and its “Manufactured for”/“Manufactured by” site fields.
What are the key supplier identifiers for audits and procurement?
Answer: Not determinable from the information available here because procurement-grade supplier identification requires the named legal entity, site address, and labeler/manufacturer attribution in FDA systems.
What TYKERB contract manufacturing (CDMO) supply chain constraints exist?
Answer: Not determinable from the information available here because the CDMO identity depends on FDA-inspected facility listings and the Orange Book site attribution.
Are there known second-source suppliers for TYKERB tablets?
Answer: Not determinable from the information available here because secondary supply chains are confirmed only via site listings and any authorized generics (if present) and change-in-manufacturer supplements.
Does tablet strength change the supplier?
Answer: Not determinable from the information available here because Orange Book listings can assign different manufacturers to different strengths.
What is the Orange Book status of TYKERB, and how does that affect supplier visibility?
Answer: Not determinable from the information available here because Orange Book status (listed drug, NDA number, labeler, and manufacturing sites) is required to connect “supplier” to “FDA-listed manufacturer.”
How do NDA holders vs. labelers affect who “supplies” TYKERB?
Answer: Not determinable from the information available here because labeler/manufacturer relationships must be read directly from the Orange Book entry.
When do TYKERB exclusivity and patent events change the supplier landscape?
Answer: Not determinable from the information available here because exclusivity and patent events require the TYKERB Orange Book patent listing and litigation/patent history tied to supplier transitions.
Do patent expirations enable generic manufacturing and add suppliers?
Answer: Not determinable from the information available here because generic entry and at-launch manufacturer identity requires ANDA approval records and labeler data.
How many TYKERB suppliers exist and what is their share of US supply?
Answer: Not determinable from the information available here because supplier count and market share require contract/manufacturing-site data and sales channel data.
What generic entry risks exist for TYKERB that could add new suppliers?
Answer: Not determinable from the information available here because generic entry depends on ANDA status, patent carve-outs, and launch timelines, none of which are supplied in the current context.
Key Takeaways
- A complete, accurate TYKERB supplier list must be derived from FDA Orange Book manufacturing-site fields tied to the specific NDA entry for TYKERB.
- API vs. finished-dose supplier identification requires mapping NDA and DMF linkages, which is not available in the current input.
- No verified supplier names can be provided without the controlling FDA listing data.
FAQs
- What is the NDA number for TYKERB that determines its Orange Book listing and manufacturer attribution?
- Which TYKERB strengths share the same manufacturing sites in the Orange Book?
- How can procurement teams verify the exact TYKERB finished-dose manufacturer for each lot?
- Do TYKERB API suppliers appear in FDA’s public databases, and how are they linked to the NDA?
- When generics or authorized alternatives enter, how does the supplier roster typically change for TYKERB?
References
- FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Orange Book database). U.S. Food and Drug Administration.
- FDA Drug Application/Facility information systems (for manufacturing site and facility inspection records). U.S. Food and Drug Administration.
More… ↓
